` Comparison: FDC vs AZN - Alpha Spread

FDC
vs
AZN

Over the past 12 months, FDC has underperformed AZN, delivering a return of -6% compared to the AZN's +26% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
FDC
AZN
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

FDC Intrinsic Value
HIDDEN
Show
AZN Intrinsic Value
HIDDEN
Show
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
F D C Ltd
NSE:FDC
359.65 INR
AstraZeneca PLC
LSE:AZN
15 110 GBX
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
FDC, AZN

FDC
AZN
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
F D C Ltd
Revenue
AstraZeneca PLC
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
FDC, AZN

FDC
AZN
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
F D C Ltd
NSE:FDC
AstraZeneca PLC
LSE:AZN
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

FDC
67.9%
AZN
81.3%
LTM 3Y Avg 5Y Avg 10Y Avg
F D C Ltd
AstraZeneca PLC

Operating Margin

FDC
10.7%
AZN
23.9%
LTM 3Y Avg 5Y Avg 10Y Avg
F D C Ltd
AstraZeneca PLC

Net Margin

FDC
10.4%
AZN
17.4%
LTM 3Y Avg 5Y Avg 10Y Avg
F D C Ltd
AstraZeneca PLC

FCF Margin

FDC
-2.7%
AZN
14.8%
LTM 3Y Avg 5Y Avg 10Y Avg
F D C Ltd
AstraZeneca PLC

ROE

FDC
9.2%
AZN
22.9%
LTM 3Y Avg 5Y Avg 10Y Avg
F D C Ltd
AstraZeneca PLC

ROA

FDC
7.8%
AZN
9.4%
LTM 3Y Avg 5Y Avg 10Y Avg
F D C Ltd
AstraZeneca PLC

ROIC

FDC
8.1%
AZN
13%
LTM 3Y Avg 5Y Avg 10Y Avg
F D C Ltd
AstraZeneca PLC

ROCE

FDC
9.1%
AZN
17.6%
LTM 3Y Avg 5Y Avg 10Y Avg
F D C Ltd
AstraZeneca PLC

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
FDC, AZN

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
FDC, AZN

Performance Gap Between FDC and AZN
HIDDEN
Show

Performance By Year
FDC, AZN

Loading
FDC
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare FDC to other stocks
LLY
Eli Lilly and Co
More expensive
vs FDC
JNJ
Johnson & Johnson
More expensive
vs FDC
ROG
Roche Holding AG
Cheaper
vs FDC
NOVN
Novartis AG
More expensive
vs FDC
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett